

How a full service CRO, accelerated PK Analysis by 66% in Early-Phase Trials

Summary

Since 2007, Spaulding Clinical has built its reputation as a full-service Phase I clinical pharmacology unit that delivers both speed and quality. To keep sponsors ahead of the curve, Spaulding continually invests in operational efficiency and cutting-edge technologies that accelerate decision-making while maintaining regulatory rigor.

Spaulding Clinical selected Aplos NCA for its ability to streamline the entire analysis process, from setup and calculation to export.



With Aplos NCA, PK projects can be set up and running in minutes

Partnering with Aplos Analytics means lightning-fast non-compartmental pharmacokinetic with streamlined, compliant reporting. No desktop installations or programming skills necessary.

Competitive Advantage



Fast turnaround is more than speed, it's a strategic advantage. Delivering accurate results first can distinguish your organization, build sponsor trust, and create new opportunities.

More results, less time

With Aplos NCA, Spaulding Clinical reduced PK analysis timelines by 66%, going from 2–3 weeks to just one, while delivering precise, reliable data without delays.



Secure and Compliant by Design

All data and results are protected with end-to-end encryption and strict access controls. Aplos NCA generates compliant and audit-ready outputs giving sponsors and regulators confidence in every analysis.



Ready to accelerate your PK workflows? Get in touch to schedule a personalized demo or start your free trial.

Contact us at info@aplosanalytics.com or visit aplosanalytics.com to learn more.